1590 results about "Heterocyclic compound" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention provides a boron-nitrogen heterocyclic compound as well as an intermediate and a preparation method thereof, the boron-nitrogen heterocyclic compound has a structure as shown in a general formula (1), and is prepared by taking compounds as shown in a formula A, a formula B and a formula C as intermediates. Compared with similar carbon skeleton molecules, the boron-nitrogen heterocyclic compound provided by the invention shows an excellent narrow-band luminescence property. The half-peak width of the emission spectrum of the boron-aza compound is as low as 6.4 nm, and meanwhile, the fluorescence quantum yield is as high as 97%.

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The invention belongs to the technical field of organic photoelectric materials, and particularly relates to a boron-nitrogen heterocyclic compound and an organic electroluminescent device thereof. The boron-nitrogen heterocyclic compound provided by the invention has relatively large steric hindrance, on one hand, molecular vibration is reduced, and the boron-nitrogen heterocyclic compound has relatively narrow half-peak width and can effectively improve the color purity of light emitted by a device; on the other hand, the distance between molecules is increased, the acting force between the molecules is weakened, quenching caused by aggregation is overcome, the luminous efficiency of the device can be improved, and the service life of the device can be prolonged.

The present invention discloses a non-aqueous electrolyte for a secondary battery and a secondary battery thereof, the electrolyte comprises an electrolyte salt, a non-aqueous solvent and an additive, the additive at least comprises: a nitrogen-containing heterocyclic compound as a first additive, a film-forming additive with a film-forming potential of less than 1.5 V (vs. Li + / Li) as a second additive, the specific structure of the additive is shown in the specification. The nitrogen-containing heterocyclic compound and the film-forming additive with the film-forming potential lower than 1.5 V (vs.Li < + > / Li) are combined for use, and the nitrogen-containing heterocyclic compound and the film-forming additive are regulated in a specific content ratio range to fully generate a synergistic effect, so that water catching and acid inhibition can be effectively realized, decomposition and gas production can be effectively inhibited at high temperature and high voltage, the stability of the electrolyte is greatly improved, and the service life of the electrolyte is prolonged. And an SEI film with excellent ion transmission capability and structure / thermal stability can be formed on the surface of the electrode, so that the first efficiency of the battery is effectively improved, and the low-temperature performance and the cycle performance of the battery are further improved.

The invention provides a carbazole-containing heterocyclic compound and an organic electroluminescent device thereof, and relates to the technical field of organic electroluminescent materials. The carbazole-containing heterocyclic compound provided by the invention has relatively high polarizability, is beneficial to improving the refractive index, and can reduce the total reflection phenomenon during light emission of the device and effectively improve the light extraction efficiency of the device when being applied to a covering layer of the organic electroluminescent device; and meanwhile, the compound has relatively high glass transition temperature and good film-forming property, and can isolate moisture and oxygen, so that the luminous efficiency and the service life of the organic electroluminescent device are further improved and prolonged. The preparation method of the compound is simple, raw materials are easy to obtain, and the compound can be widely applied to the fields of organic thin film transistors, panel display and the like and has good application effects and industrialization prospects.

The invention discloses a novel substituted heterocyclic compound with GSPTs / CK1a double-target degradation activity, and particularly discloses a compound which has the GSPTs / CK1a double-target degradation activity and is shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer of the compound. The compound can be used for preventing or treating diseases related to GSPTs / MYC / CK1a / WNT targets or signal pathways.

Disclosed in the present invention is a novel substituted heterocyclic compound having VAV1 target degradation activity. Specifically disclosed is a compound serving as a VAV1 target degradation agent and having the structure of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, isotopic substituent or isomer of the compound. The compound can be used for preventing or treating diseases related to VAV1 targets or signaling pathways.

Disclosed herein are heterocyclic compounds that activate GLP-1R pathways. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the GLP-1R agonists are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes, obesity, and other diseases or conditions dependent on GLP-1R pathways.

The invention relates to application of a heterocyclic compound as a fluorescent probe. The structural formula of the heterocyclic compound is shown as a general formula I, and R1, R2, R3, R4, R5, R6, R7 and R8 are independently one of hydrogen, alkyl, hydroxyl, phenyl, hydroxyphenyl, indole and oxymethyl. According to the present invention, the heterocyclic compounds represented by the general formula I can be specifically positioned in mitochondria, and have long fluorescence lifetime, such that the heterocyclic compounds are suitable for being used as mitochondria fluorescence probes.

The present invention relates to a heterocyclic compound capable of inhibiting IL-17A, a preparation method therefor, an intermediate, and a use thereof. In particular, the present invention relates to the compound shown in general formula (I), a preparation method therefor, an intermediate, a pharmaceutical composition including the compound shown in general formula (I), and a use of the compound shown in general formula (I) or the pharmaceutical composition thereof in preparing a drug which treats / prevents IL-17A-mediated diseases. The substituents in general formula (I) have the same definitions as in the description.

The invention belongs to the technical field of surface engineering protective coatings, and discloses a nitrogen heterocyclic compound modified corrosion-resistant high-entropy alloy coating as well as a preparation method and application thereof. The preparation method comprises the following steps that firstly, a magnetron sputtering technology is adopted, a CoCrFeMnNi target serves as a cathode target material, and a corrosion-resistant high-entropy alloy coating is obtained through deposition on the surface of a base body; and then, in a three-electrode system, the corrosion-resistant high-entropy alloy coating is placed in an electrolyte containing a nitrogen heterocyclic onium salt compound to be subjected to electro-deposition, and the nitrogen heterocyclic compound modified corrosion-resistant high-entropy alloy coating is prepared. The corrosion-resistant inorganic-organic hybrid coating prepared by the invention has excellent corrosion resistance, can keep high stability and durability in a complex corrosion environment, and has relatively high corrosion potential and relatively low corrosion current density. The coating can remarkably prolong the service life of a structural base material, is suitable for various harsh working conditions, and provides an efficient and reliable protection solution for industrial application.

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

The invention belongs to the field of medicines, and relates to a heterocyclic compound as shown in formula (I), which can be used as a voltage-gated sodium channel inhibitor, especially has an excellent inhibition effect on Nav1.8, has excellent selectivity and pharmacokinetic properties, and can be applied to prevention, alleviation and / or treatment of voltage-gated sodium channel related diseases.

A polishing liquid which reduces the occurrence of erosion and scratches on a surface to be polished of an object to be polished having a cobalt-containing film after polishing in a case where the polishing liquid is applied to CMP of the object to be polished is provided. In addition, a chemical mechanical polishing method using the above-mentioned polishing liquid is provided. The polishing liquid is a polishing liquid used for chemical mechanical polishing of an object to be polished having a cobalt-containing film. The polishing liquid includes colloidal silica, an organic acid, a specific nitrogen-containing aromatic heterocyclic compound and hydrogen peroxide, and has a pH of 8.5 to 12.

To provide a salt-forming compound, which is a salt of a xanthene-based compound, exhibiting higher coloring strength and higher color development stability after heat and light history compared with traditional ones, and also to provide a resin composition and a color filter.SOLUTION: There is provided a xanthene-based compound which is a salt composed of an anion forming a xanthene-based chromophore having an anionic functional group represented by general formula (1), and a cation composed of an aromatic nitrogen-containing heterocyclic compound having a linear or branched, saturated or unsaturated hydrocarbon group (optionally containing an ether bond and / or an ester bond within the hydrocarbon group).SELECTED DRAWING: None

The invention belongs to the technical field of photoelectric materials, and relates to a nitrogen-containing heterocyclic compound and an organic electroluminescent element containing the nitrogen-containing heterocyclic compound. The compound has a structure represented by formula (1): wherein L is selected from a single bond, a substituted or unsubstituted C6-C60 arylene group, and a substituted or unsubstituted C3-C60 heteroarylene group, o is an integer from 1 to 3, and when o is 2 or greater, L are the same as or different from each other. The organic electroluminescent element prepared from the compound has higher current efficiency and longer service life, and can be used as an N-type charge generation layer material for preparing the organic electroluminescent element.

A method for producing an aromatic heterocycle-substituted difluoroacetic acid derivative having a partial structure represented by the formula (III), by reacting an N-oxido aromatic heterocyclic compound having a partial structure represented by the formula (I) with tetrafluoroethylene in the presence of a compound represented by the formula (II): R—YH, in a solvent selected from an aromatic hydrocarbon solvent, an ester solvent and an ether solvent:

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention discloses a novel substituted heterocyclic compound with GSPTs / CK1a double-target degradation activity, and particularly discloses a compound which has the GSPTs / CK1a double-target degradation activity and is shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer of the compound. The compound can be used for preventing or treating diseases related to GSPTs / MYC / CK1a / WNT targets or signal pathways.

The invention relates to the technical field of medicines. The invention particularly relates to a heterocyclic compound, a pharmaceutical salt and a pharmaceutical composition thereof, which can be used for reducing the concentration of plasma Lp (a).

The present invention provides a quinazolinone-fused five-membered heterocyclic derivative with a structure represented by formula (I-A). Experimental results show that the compound provided by the present invention has good inhibitory activity against MAT2A, has inhibitory activity against the proliferation of cancer cells with an MTAP deletion mutation, and can be used for treating and / or preventing MAT2A-related cancer diseases.

The invention provides a heterocyclic compound and a pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical chemistry. The series of heterocyclic compounds prepared by the invention have efficient sedative, hypnotic and / or anesthetic effects, can control the state of epilepsy, also have an analgesic effect, and have great significance for clinically preparing drugs with the analgesic effect and drugs with anesthetic, sedative, hypnotic and / or capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

The invention relates to a nitrogen-containing heterocyclic ring compound and application thereof, and particularly discloses a compound as shown in a formula (II), and a stereoisomer and pharmaceutically acceptable salt thereof.

The invention discloses a dual-band acridine formic acid anthracene methyl ester photocatalyst as well as a preparation method and application thereof, and belongs to the field of heterocyclic compounds. The invention designs and synthesizes a novel acridine formic acid anthracene methyl ester photocatalyst, which has good compatibility in two wavebands of 365 nm and 405 nm, can realize photocatalysis of disulfide compounds and aryl formyl peroxide compounds, and provides a new thought for preparation of sulfoxide compounds with asymmetric structures; the reaction conditions are mild, the reaction time is short, the photocatalyst can be recycled, the circulation loss is low, the circulation efficiency is high, the production efficiency is greatly improved, and the production period and cost are reduced; the product is free of transition metal residues and high in yield.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Provided is a compound and so on having aldehyde dehydrogenase 2 (ALDH2) activation effect. A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound being represented by the following formula (1):whereinA is a heterocycle,R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl,R3 is an alkyl, an alkenyl, or an alkynyl, andX1 and X2 are each independently a halogen.

The invention discloses a nitrogen-containing heterocyclic compound and application thereof. The nitrogen-containing heterocyclic compound has a structure as shown in a formula (I). The compound provided by the invention has an excellent glutamine cyclase inhibition effect, can be applied to treatment of tumors, immune diseases, neurological diseases or aging, and has a good application prospect.